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Methylome sequencing in triple-negative breast
cancer reveals distinct methylation clusters with
prognostic value
Clare Stirzaker1,2,*, Elena Zotenko1,2,*, Jenny Z. Song1, Wenjia Qu1, Shalima S. Nair1,2, Warwick J. Locke1,2,
Andrew Stone1,2, Nicola J. Armstong1,3, Mark D. Robinson1,4, Alexander Dobrovic5, Kelly A. Avery-Kiejda6,
Kate M. Peters7, Juliet D. French7,8, Sandra Stein9, Darren J. Korbie10, Matt Trau7,10, John F. Forbes11,
Rodney J. Scott6,12, Melissa A. Brown7, Glenn D. Francis9,10 & Susan J. Clark1,2
Epigenetic alterations in the cancer methylome are common in breast cancer and provide
novel options for tumour stratification. Here, we perform whole-genome methylation capture
sequencing on small amounts of DNA isolated from formalin-fixed, paraffin-embedded tissue
from triple-negative breast cancer (TNBC) and matched normal samples. We identify dif-
ferentially methylated regions (DMRs) enriched with promoters associated with transcription
factor binding sites and DNA hypersensitive sites. Importantly, we stratify TNBCs into three
distinct methylation clusters associated with better or worse prognosis and identify 17 DMRs
that show a strong association with overall survival, including DMRs located in the Wilms
tumour 1 (WT1) gene, bi-directional-promoter and antisense WT1-AS. Our data reveal
that coordinated hypermethylation can occur in oestrogen receptor-negative disease, and
that characterizing the epigenetic framework provides a potential signature to stratify TNBCs.
Together, our findings demonstrate the feasibility of profiling the cancer methylome with
limited archival tissue to identify regulatory regions associated with cancer.
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T
riple-negative breast cancers (TNBCs) comprise a hetero-
geneous group of cancers with varying prognoses,
presenting a challenge for effective clinical management.
TNBC is clinically defined by the absence of oestrogen receptor
(ER) and progesterone receptor expression, and neither over-
expression nor amplification of human epidermal growth factor
receptor 2 (HER2)1,2. TNBC represents B15–20% of all newly
diagnosed breast cancer cases and is generally associated with
high risk of disease recurrence and shorter overall survival
compared with non-TNBC3. Broadly, TNBC patients can be
categorized into two distinct groups; those that succumb to their
disease within three to five years regardless of treatment and
those that remain disease-free to the extent that their overall
survival exceeds that of non-TNBC patients (that is,
approximately 48 to 10 years post diagnosis)4,5. Currently,
methods by which TNBC patients are stratified into high- and
low-risk subgroups remain limited to staging by clinicopatho-
logical factors such as tumour size, level of invasiveness and
lymph node infiltration. However, unlike other breast cancer
subtypes, TNBC outcome is less closely related to stage6. Thus,
there is a clear need to identify a robust method by which TNBC
patients can be stratified by prognosis, to enable more informed
disease management.
Current efforts to stratify early breast cancer prognosis have
primarily focused on multi-gene expression signatures and all
have received varying degrees of acceptance7. In addition to
multi-gene expression assays, DNA methylation signatures are
being assessed as potential molecular biomarkers of cancer8.
A number of studies have documented aberrant methylation
events in breast carcinogenesis and identified specific DNA
methylation biomarkers that have significant diagnostic and
prognostic potential9–12. Several studies have also identified DNA
methylation signatures that can distinguish between breast cancer
subtypes13–16, and others that may be predictive of treatment
response17–19.
Despite growing interest in the prognostic significance of DNA
methylation in breast cancer, there have been no studies
specifically investigating the DNA methylation profile of human
TNBC and its association with disease outcome. Here we carry
out genome-wide DNA methylation profiling of formalin-fixed
paraffin-embedded (FFPE) triple-negative clinical DNA samples,
using affinity capture of methylated DNA with recombinant
methyl-CpG binding domain of MBD2 protein, followed by next
generation sequencing (MBDCap-Seq)20,21. This high-resolution
technique allows for genome-wide methylation analysis of CpG
rich DNA22,23. Using MBDCap-Seq, we identify regional
methylation profiles specific to TNBC, which we validate using
methylation data extracted from TCGA breast cancer cohort13.
Importantly, we also report the first potential prognostic
methylation signature of survival, specific for TNBC that now
warrants further study in larger cohorts.
Results
Genome coverage of MBDCap-Seq. To delineate regions
assayable with MBDCap-Seq, we first profiled fully methylated
(CpG methyltransferase SssI-treated blood sample) DNA.
Computational analysis of SssI MBDCap-Seq revealed that
MBDCap-Seq can robustly assess the methylation status of
230,655 regions spanning a total of 116Mbp, comprising
5,012,633 CpG dinucleotides, or B18% of the total number of
CpG sites in the human genome (see Methods; Supplementary
Fig. 1a). The assayed CpG sites span 91% of all CpG islands;
84% CpG island shores; 72% RefSeq promoters; 38% introns
and 31% exons. We next compared coverage of MBDCap-Seq
with the Illumina HumanMethylation450K (HM450K) array
(Supplementary Fig. 1b) and found that MBDCap-Seq inter-
rogates additional 4,740,327 CpG sites as compared with the
high-density HM450K array.
A major advantage of the MBDCap-Seq method is the ability
to interrogate regional blocks of hypermethylation, that is,
methylation spanning consecutive CpG sites, which commonly
occurs in cancer. We compared regional MBDCap-Seq coverage
to coverage of HM450K arrays (Supplementary Fig. 1a) and
found that while MBDCap-Seq and HM450K arrays have similar
regional coverage of CpG islands (91 versus 81%) and RefSeq
promoters (71 versus 83%), MBDCap-Seq regional coverage of
shores (77 versus 28%), enhancers (12 versus 2%) and insulators
(11 versus 1%) is much greater, highlighting the potential
advantage of MBDCap-Seq in screening novel functional regions
of the cancer methylome.
To determine if MBDCap-Seq can also provide accurate
methylation analysis from FFPET DNA, we compared DNA
methylation profiles from DNA isolated from fresh frozen (FF)
and FFPET of matching tumour and lymph node samples.
We show that MBDCap-Seq from FFPET provides equivalent
methylation to FF DNA (Pearson Correlation Coefficient of
0.95 and 0.86, respectively) (Supplementary Fig. 2a) and that
MBDCap-Seq and HM450K array performed on the same FFPET
tumour and lymph node DNA show high concordance (0.79 and
0.77, respectively) (Supplementary Fig. 2b–d). We also show
that there are regions uniquely covered by MBDCap-Seq, for
example, at enhancers and insulator elements (Supplementary
Fig. 2e,f).
Differentially methylated regions in TNBCs. To identify dif-
ferentially methylated regions (DMRs) in TNBCs, we first pro-
filed FFPET DNA using MBDCap-Seq from a discovery cohort of
19 Grade 3 TNBC tumours and six matched normal samples
(Supplementary Table 1) and analysed the data with a novel
computational pipeline for comparative statistical analysis of
MBDCap-Seq samples (see Methods; Supplementary Fig. 3). We
identified 822 hypermethylated and 43 hypomethylated statisti-
cally significant DMRs (FDRo0.05), harbouring 64,005 and 623
CpG sites, respectively, compared with matched normal samples
(see Fig. 1a,b; Supplementary Data 1) and validated sample-spe-
cific differential methylation using Sequenom DNA methylation
analysis (Supplementary Fig. 4). Next, we determined the geno-
mic location of the DMRs and found that CpG islands, CpG
island shores and promoters are significantly overrepresented
(hypergeometric test; P value o0.0001) in the 822 hypermethy-
lated regions and underrepresented in the 43 regions of
hypomethylation (Fig. 1c; see Methods). Notably, ChromHMM-
annotated HMEC promoters24 and polycomb repressed regions
were also significantly enriched (hypergeometric test; P value
oo0.001) for gain of methylation in the breast cancer samples.
Finally, we validated example DMRs in an independent cohort of
31 TNBCs and 15 normal breast samples and a panel of cell lines
(Supplementary Table 2). We performed Sequenom methylation
analysis on five of the 822 hypermethylated regions spanning the
CpG island promoters of NPY, FERD3L, HMX2, SATB2 and
C9orf125 (Supplementary Fig. 5). The levels of methylation
detected in the normal samples were uniformly low, whereas the
five DMRs showed striking hypermethylation in the TNBCs
(Fig. 1d) and 24 breast cancer cell lines (Fig. 1e).
Functional characterization of hypermethylated genes. To
predict the potential functional significance of the 822 DMRs
identified in the TNBC, we first determined which regions
overlapped with promoters and genes and found that
the DMRs were associated with 513 RefSeq promoters, which
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corresponded to 308 genes (Supplementary Data 2). We used the
DAVID functional annotation tool25 to annotate this set of
genes. Visualization of statistically significantly (FDR o0.05)
overrepresented gene sets revealed two largely non-overlapping
groups of genes26 (see Methods; Supplementary Fig. 6;
Supplementary Table 3). One group is annotated with keywords
‘DNA-BINDING’, ‘TRANSCRIPTION’, ‘TRANSCRIPTION
REGULATION’, ‘HOMEOBOX’, ‘DEVELOPMENTAL
PROTEIN’ and ‘DIFFERENTIATIONS’ and contains
approximately 100 genes, mostly transcription factors, such as
BARHL2, DLX6, OTX2, RUNX1T1 and TAC1. The second group
is annotated with keywords ‘SIGNAL’, ‘CELL MEMBRANE’,
‘TRANSDUCER’, ‘GLYCOPROTEIN’ and ‘G-PROTEIN
COUPLED RECEPTOR’ and contains genes involved in
signalling pathways such as ADRB3, GHSR, NPY and ROBO3.
To determine whether promoter hypermethylation was
potentially involved in gene silencing, we examined TCGA
expression data for the 308 genes affected by promoter
hypermethylation (see Methods for the analysis of TCGA
expression data for TNBC samples; 89 tumour and eight
matched normal samples). We found that genes with promoter
hypermethylation are enriched in downregulated genes (71
out of 245 genes, for which expression data are available, are
downregulated; hypergeometric test; FC 1.73; P value oo0.001)
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Figure 1 | MBDCap-seq identifies DMRs in discovery cohort. A heatmap showing methylation profile of 822 hypermethylated (a) and 43 hypomethylated
regions (b) across a cohort of 19 tumour and six matched normal samples in the discovery cohort. Columns are samples and rows are regions. The level of
methylation (number of reads normalized with respect to fully methylated sample) is represented by a colour scale—blue for low levels and red for high
levels of methylation. (c) A bar plot showing association of DMRs across functional/regulatory regions of the genome—(i) CpG islands and shores,
(ii) RefSeq transcripts and (iii) Broad ChromHMM HMEC annotation. The height of the bars represents the level of enrichment measured as a ratio
between the frequency of hypermethylated (pink) or hypomethylated (blue) regions overlapping a functional element over the expected frequency if such
overlaps were to occur at random in the genome. Statistically significant enrichments (P value o0.05; hypergeometric test) are marked with an asterisk.
(d) Sequenom validation of five hypermethylated regions—FERD3L, C9orf125, HMX2, NPYand SATB2—is shown for an independent cohort of TNBC samples
(normal n¼ 15; tumour n¼ 33) and (e) a panel of breast cancer cell lines (normal n¼ 3; cancer n¼ 24). For each region, box plots displaying the
distribution of methylation levels are shown in grey/blue for normal/tumour samples/cell lines. (f) A bar plot showing enrichment of genes with promoter
hypermethylation in sets of genes that are up-/downregulated in the TCGA cohort of TNBC tumours as compared with matched normal samples. The
height of the bars represents the level of enrichment measured as a ratio between the observed number of up-/downregulated genes with promoter
hypermethylation to the expected number of such genes. (g) A Venn diagram showing overlap between genes with promoter hypermethylation, genes
downregulated in TCGA TNBC cohort (hypergeometric test; FC 1.73; P value oo0.001) and genes with two or more mutations (hypergeometric test; FC
1.92; P value oo0.001) in TCGA breast cancer cohort.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6899 ARTICLE
NATURE COMMUNICATIONS | 6:5899 | DOI: 10.1038/ncomms6899 |www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
and are depleted in upregulated genes (28 out of 245 genes are
upregulated; hypergeometric test; FC 0.53; P value oo0.001)
(Fig. 1f).
To identify potential driver events, we overlapped the 308
hypermethylated genes with genes recurrently mutated in breast
cancer in TCGA13 (Fig. 1g). We found that out of 308 genes with
promoter methylation, 51 are mutated (hypergeometric test; FC
of 1.92; P value oo0.001) and 12 (C9orf125, COL14A1, ENPP2,
ERG2, PLD5, ROBO3, RUNX1T1, SEMA5A, TBX18, TSHZ3,
ZBTB16 and ZNF208) are both mutated and downregulated.
Of these, both ROBO3 and SEMA5A are part of the axon
guidance pathway recently implicated in tumour initiation and
progression27,28. Interestingly, promoter hypermethylation
affects, in total, seven members of the axon guidance pathway
(CRMP1, GDNF, GFRA1, MYL9, ROBO1, ROBO3 and SEMA5A)
with four members (GFRA1, MYL9, ROBO3 and SEMA5A)
downregulated.
Differentially methylated regions specific to TNBCs. We next
asked if any of the 822 DMRs were also found in ER or ERþ
breast cancer. We used TCGA breast cancer methylation cohort,
which comprises HM450K data for 354 ERþ and 105 ER
breast tumours (73 of which are TNBCs) and 83 normal breast
samples (see Methods for the analysis of TCGA methylation
data). Of the 822 DMRs regions identified in the MBDCap-seq
methylation discovery set, 770 DMRs are interrogated by a total
of 4,987 HM450K probes from the TCGA data set. We found that
while the majority of these probes are not methylated in breast
normal tissue, they were hypermethylated to various degrees in
both ERþ and ER breast cancers (Fig. 2a). Both ERþ and
ER subtypes also contained samples with minimal methylation
across all probes, as well as those that displayed extensive
methylation more representative of a CpG island methylator
phenotype (CIMP)29.
Next, we asked whether any of the DMRs were TNBC specific.
Out of 4,987 HM450K probes, we found that 5% (282/4,987) were
significantly hypermethylated in TNBCs (t-test; mean differential
(diff) methylation 410%; P value o0.05) compared with the
ERþ tumours and the rest of the ER ve tumours. Using
methylation values of 282 TNBC-specific probes, we were able to
classify tumour samples in the TCGA HM450K cohort into
TNBCs and non-TNBCs with sensitivity of 0.72 sensitivity,
specificity of 0.94 and AUC 0f 0.90 (Fig. 2b). From the 282
TNBC-specific probes, we identified 36 TNBC-specific regions
(harbouring at least three or more 450K TNBC-specific probes)
that primarily overlap promoters and/or gene bodies
(Supplementary Table 4; Supplementary Fig. 7). The regions
predominantly overlap genes-encoding zinc fingers and tran-
scription factors and intergenic regions that are commonly
marked by polycomb in HMECs. An example of two such TNBC-
specific regions are located in the promoters of genes-encoding
zinc finger proteins ZNF154 and ZNF671 on chromosome 19
(Fig. 2c). Both promoters have low methylation levels in normal
breast and increased levels of methylation in TNBC samples as
compared with ERþ cancer. The distribution of expression
values mirrors the methylation status, with normal samples
showing the highest levels of expression and TNBC tumours
showing the lowest levels of expression (Fig. 2d), suggesting
silencing by methylation of both ZNF154 and ZNF671 in TNBC
tumours.
DNA methylation profile can stratify TNBCS. To identify
DMRs that potentially stratify TNBCs, we used unsupervised
cluster analysis on methylation of the 4,987 HM450K probes and
identified three distinct groups of TNBC tumours from the
TCGA data sets (Fig. 3a; see Methods). Survival analysis revealed
that the largely hypomethylated cluster (blue cluster) was asso-
ciated with better prognosis as compared with the other two more
highly methylated clusters (orange and red clusters) (Fig. 3b).
In particular, the medium methylated cluster (orange cluster)
comprises samples with the worst prognosis (Cox proportional
hazards model; hazard ratio¼ 8.64; P value¼ 0.005) as com-
pared with the good prognosis TNBC cluster (blue cluster). More-
over, there was no association between the induced clusters and
survival for ERþ or non TNBC samples (Supplementary Fig. 8).
Next, we determined to what extent regional methylation
stratify TNBCs into good and bad prognosis groups. Survival
analysis identified 190 probes that were associated with survival
in TCGA TNBC samples (Cox proportional hazards model;
P value o0.05) in both univariate and multivariate analyses (see
Methods). We observed regional association (at least three
concordantly located survival probes) for 17 regions; 14 genomic
regions with poor survival and three genomic regions for good
survival (Table 1; Supplementary Fig. 9). Each of the individual
Kaplan–Meier plots for individual CpG sites in each region
showed excellent survival separation, highlighting the potential
value as prognostic biomarkers (Fig. 3c–e; Supplementary Fig. 9).
The genomic location of these regions vary with four regions
located in a promoter (SLC6A3, C6orf174, WT1-AS and ZNF254),
seven in the gene body only (DMRTA2, LHX8, WT1, WT1-AS,
HOXB13, ECEL1, SOX2-OT) and five in intergenic regions
(Table 1). Interestingly, with the exception of the region encoded
by chr10: 102,409,068-102,409,766, all prognostic regions overlap
DNase1 hypersensitive sites (ENCODE) and are marked with a
polycomb signature in HMEC cells and many contain numerous
conserved transcription factor binding sites (TRANSFAC30)
(Table 1). Furthermore, we show that the average level of
methylation of CpG sites in the 17 potential prognostic regions is
higher in the two poor survival groups and is lower in the normal
and low-risk groups (Supplementary Fig. 10).
A striking example of regional hypermethylation across
consecutive CpG probes that shows statistical significance as a
prognostic marker of survival are the DMRs spanning the
bi-directional promoter and gene bodies of WT1 gene and its
antisense counterpart, WT1-AS (Fig. 3f). Wilms tumour protein
(WT1) is a zinc finger transcription factor overexpressed in
several tumour types including breast31. We observe an
association between high level of methylation in chr11-11623
and chr11-1210, regions spanning the gene bodies of WT1 and
WT1-AS, respectively, and poor survival in TCGA TNBC cohort
(Fig. 3f). Moreover, increased levels of methylation in these
regions are also associated with increased expression of WT1
(chr11-11623) and WT1-AS (chr11-1210) in TNBC patients
(Supplementary Fig. 11). Conversely, we observe that TNBC
patients with high methylation in chr11-4047, a region spanning
bi-directional promoter ofWT1 andWT1-AS, survive longer than
TNBC patients with low methylation in this region.
Discussion
The prognostic stratification of TNBC patients remains one of the
most significant challenges in breast cancer research. While
current efforts have primarily focused on the development of
multi-gene expression classifiers to inform patient outcome, here
we demonstrate the significant prognostic potential of DNA
methylation biomarkers for the stratification of TNBCs. We
performed genome-wide DNA methylation profiling on TNBC,
identified novel regions of differential methylation, and validated
regions specific for TNBC using TCGA methylation data as an
independent cohort. Strikingly, unsupervised cluster analysis of
DMRs stratified TNBC patients into populations of high, medium
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6899
4 NATURE COMMUNICATIONS | 6:5899 | DOI: 10.1038/ncomms6899 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
or low-risk disease outcome. In addition, using both univariate
and multivariate Cox proportional hazard models, we identified
17 DMRs significantly associated with TNBC patient survival
(P-value o0.05). Critically, our classifiers paralleled the
biologically relevant time-dependent pattern of patient outcome,
whereby TNBC patients are most vulnerable to disease-associated
death within the first five years following diagnosis, highlighting
their potential use as a valuable prognostic application.
ER– tumours
(n=105)
Normal tissue
(n=83)
ER+ tumours 
(n=354)
4,987 DMR
probes
0.0 0.2 0.4 0.6 0.8 1.0
Methylation beta values
DMR
CpG islands
HM450 probes
0.0
0.2
0.4
0.6
0.8
1.0
cg2
67
05
68
8
cg0
32
15
10
5
cg1
20
74
02
5
cg1
92
46
11
0
cg1
19
77
68
6
cg0
80
48
22
2
cg2
40
16
93
9
chr19-31544 chr19-6109
ZNF154 ZNF671
5 kb
cg0
31
42
58
6
cg1
12
94
51
3
cg0
56
61
28
2
cg2
17
90
62
6
cg2
70
49
76
6
cg0
32
34
18
6
cg0
86
68
79
0
cg1
25
06
93
0
0.0
0.2
0.4
0.6
0.8
1.0
β-V
al
ue
Normal tissue ER+ and other ER- tumours TNBC tumoursKey:
Normal ER+ TNBC
3
4
5
6
ZNF671 (mean diff = −0.85 P value = 5.50e−21)
Normal ER+ TNBC
2
3
4
5
ZNF154 (mean diff = −0.51 P value = 9.04e−10)
Ex
pr
es
sio
n
Specificity
Se
ns
itiv
ity
0.0
0.2
0.4
0.6
0.8
1.0
1.0 0.8 0.6 0.4 0.2 0.0
AUC: 0.90 (0.85–0.96)
ROC analysis
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Table 1 | Summary of 17 DMRs associated with overall survival in TCGA TNBC.
Chr Start End RefSeq
Location
CpG
island
CpG
shore
Dnase
hypersensitive
site
Conserved
transcription
factor binding
sites (Z score
cutoff¼ 2.33)
ChromHMM
HMEC
polycomb
Prognostic
probes
Gene function/
location
Poor prognosis
chr1 50,658,646 50,659,783 DMRTA2* Yes No Yes GRa Yes 3 Doublesex- and Mab-
3-related transcription
factor
chr1 75,368,128 75,368,976 LHX8* Yes Yes Yes NA Yes 3 Homeobox protein
Lhx8
chr10 102,409,068 102,409,766 Yes Yes No STAT1b, NK-kB,
CREB, NF-Y,
CEBPa
Yes 5 Intergenic region,
ChromHMM
polycomb marked
chr11 32,404,535 32,407,465 WT1* Yes Yes Yes EGR1, EGR2,
EGR2, NF1,
LMO2, RFX1,
MIF1, CREB,
cJUN, ATF,
ATF2
Yes 5 Wilms tumour protein,
transcription factor
chr11 32,416,010 32,417,947 WT1-AS* Yes Yes Yes NA Yes 4 Wilms tumour protein,
antisense transcipt
chr13 27,398,788 27,401,867 Yes Yes Yes NA Yes 4 Intergenic region,
ChromHMM
polycomb marked
chr14 56,330,541 56,332,135 Yes Yes Yes USF1, MAX1,
c-MYC
Yes 3 Intergenic region,
ChrommHMM
polycomb
chr17 44,159,065 44,159,578 HOXB13* Yes Yes Yes HSF1, HSF2 Yes 3 Homeobox gene
family, transcription
factor
chr2 233,058,433 233,060,592 ECEL1* Yes Yes Yes NRSF, PAX2,
STAT5A, YY1,
AHR, GATA2,
AP2
Yes 3 Zinc-containing typeII
integral-membrane
protein
chr3 182,923,564 182,924,686 SOX2-OT* No No Yes NA Yes 4 Non-protein coding
RNA gene
chr5 1,498,811 1,499,696 SLC6A3w Yes Yes Yes NA Yes 3 Neurotransmitter
reporter
chr6 27,620,848 27,621,582 No No Yes NA No 3 ChromHMM
promoter marked,
Intergenic region
chr6 127,881,341 127,882,455 C6orf174*,w No Yes Yes STAT5A, FOXC1 Yes 6 Chromosome 6 open
reading frame SOGA3
protein coding region
chr7 121,726,837 121,728,266 Yes Yes Yes CHX10 Yes 4 ChromHMM
polycomb marked
Good prognosis
chr11 32,413,697 32,415,714 WT1/WT1-
ASw
Yes Yes Yes E47, AP4,
c-MYC, ARNT
Yes 5 Bi-directional
promoter of WT1/
WT1-AS transcription
factor
chr19 24,061,637 24,062,272 ZNF254*,w No No Yes NA No 4 Zinc finger
protein,transcriptional
regulation
chr22 44,641,414 44,642,542 Yes Yes Yes NA Yes 3 Intergenic region,
ChromHMM
promoter
DMR, differentially methylated region; NA, not available; TNBC, triple-negative breast cancer.
*Gene body.
wPromoter.
Figure 3 | Methylation profile stratifies TNBC tumours into survival subgroups. (a) Unsupervised clustering with 4,987 HM450K probes overlapping
822 hypermethylated DMRs identified in the discovery cohort separates TCGA TNBC tumours (n¼ 73) into three main clusters. The heatmap shows the
methylation profile of TCGA TNBC tumours and cluster dendrogram. The three clusters are colour-coded with the red cluster exhibiting the highest
methylation (TNBC.high), the blue cluster exhibiting the lowest methylation (TNBC.low) and the orange cluster exhibiting an intermediate level of
methylation (TNBC.medium). b; methylation beta value. (b) A Kaplan–Meier plot showing survival curves for the patients in the three clusters defined in
a. In addition, individual regions of hypermethylation in the discovery cohort overlap with survival-associated probes in the TCGA cohort, including (c)
intergenic loci, (d) intragenic loci (for example, the HOXB13 gene body) and (e) promoter associate loci (for example, ZNF254 promoter). (f) Association
with survival for three adjacent regions—chr11-11623, chr11-4047 and chr11-1210—spanning the WT1/WT1-AS locus is shown. These three regions are
hypermethylated in the discovery cohort and overlap several probes showing statistically significant association with overall survival in both univariate and
multivariate analyses. For each region, the methylation profile of TCGA TNBC tumour (n¼ 73) and adjacent normal samples (n¼9) across overlapping
survival probes is shown as a heatmap. The Kaplan–Meier plots for each of the overlapping survival probes is shown as well with corresponding hazard
ratios and P values from Cox proportional hazards model; values in parentheses correspond to multivariate analysis. HR, hazard ratio.
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The DNA methylation aberrations we identified in the TNBC
samples follow specific patterns common to many cancer types32.
For instance, hypermethylation events were localized to CpG
islands and shores, while hypomethylation occurred globally
across intragenic regions32. We observed a strong co-localization
of the hypermethylated regions with H3K27me3 marked
(polycomb repressed) regions in HMEC cells, supporting the
finding that many polycomb-regulated genes are predisposed to
aberrant methylation in cancer33. We identified 308 genes
affected by promoter hypermethylation and functional analysis
revealed significant enrichment of genes and transcription factors
involved in development and differentiation, as well as DNA
binding, homeobox proteins and transcriptional regulation.
Hypermethylation of homeobox genes has been previously
reported in breast cancer and associated with disease
progression and poor patient prognosis15,16,34,35. Genes
encoding glycoproteins were also enriched in the functional
analysis. A significant function of glycoproteins is that of
directing immune response36. This is particularly poignant
since several gene expression modules associated with immune
response have been used to predict TNBC patient outcome37–41.
Many of the aberrant cancer promoter hypermethylation events
affect genes already silenced in the tissue of origin and therefore
considered to be passenger events that do not actively contribute
to cancer initiation or progression42. To identify potential driver
methylation events, we highlighted genes that were both
downregulated in TNBC tumours and recurrently mutated in
breast cancer. Twelve methylated genes were identified as both
mutated and downregulated, including ROBO3 and SEMA5A that
are a part of the axon guidance pathway, recently implicated in
tumour initiation and progression27. In total, promoter
hypermethylation affects seven members of the axon guidance
pathway. Although the mechanism by which axon guidance
drives cancer progression is not completely understood, our data
support a potential causal role for DNA methylation for many of
these family members in TNBCs.
Using an independent TNBC cohort from the TCGA data, we
validated 36 TNBC DMRs comprising 20 genes. Strikingly, four
of the 20 genes encoded zinc finger proteins (ZNFs). Individual
ZNFs and even some clusters of ZNF genes have been found
hypermethylated and silenced in several tumour types43–46. In
addition, methylation of other ZNF genes have potential
prognostic value in prostate and bladder cancer47,48. Although
the mechanisms by which aberrant ZNF expression facilitates
oncogenesis are not completely understood, ZNFs are included in
two independently derived, TNBC specific, multi-gene expression
classifiers (TN45 and Buck 14)38,39.
Recent studies have identified non-TNBC as more heavily
methylated compared with TNBC16. In our study, we found that
a distinct population of both ERþ and ER tumours are
associated with extensive methylation across the DMRs, more
representative of a CpG island methylator phenotype (CIMP)29.
Interestingly, a previous report describes the breast-CIMP
(B-CIMP) group comprising solely ERþ tumours16; however,
our results show that coordinated hypermethylation can also
occur in ER disease. We also identified three distinct
methylation clusters of TNBC tumours based on our DMRs.
The largely hypomethylated profile was associated with better
survival within the first five years post diagnosis compared with
the more heavily methylated subtypes. Interestingly, the medium
methylated cluster was associated with the worst survival. Proof
of concept that methylation can be used to stratify breast cancer
subtypes was recently demonstrated by TCGA, where DNA
methylation data were used to classify breast cancer into five
distinct subtypes; however, each of the five methylation groups
were represented by multiple tumour subtypes and the
relationship between methylation and prognosis was not
explored13. Here, we also identified 17 individual DMRs
capable of stratifying TNBC patients into good and poor
prognosis groups. Notably, these regions predominately overlap
with DNAaseI hypersensitive regions and contain conserved
transcription factor binding sites highlighting their potentially
significant role in transcriptional regulation. Of the genes listed,
many, including WT1, WT1-AS, DMRTA1 and HOXB13, have
been previously identified as hypermethylated in numerous
cancer subtypes including breast cancer49–52, although
associations with patient prognosis were not defined in these
studies.
Finally, three ‘survival’ DMRs span the bi-directional promoter
and gene bodies of WT1 gene and its antisense counter-part
WT1-AS. WT1 is an extensively studied transcription factor
essential for normal development of the urogenital system and
deregulated across many cancer types31. In breast cancer, high
mRNA levels of WT1 were reported to be associated with poor
patient survival53 and positive modulation of expression of WT1
by its antisense transcript WT1-AS54,55. Our observed patterns of
methylation and survival support an extensive body of evidence
on the tight epigenetic transcriptional regulation of WT1 and its
role in breast cancer prognosis. More specifically, high levels of
methylation across regions spanning gene bodies of WT1 and
WT1-AS genes correlate with elevated levels of expression and
poor survival, whereas hypermethylation spanning the bi-
directional promoter is associated with decreased WT1 and
WT1-AS expression and improved survival.
Cumulatively, the work presented here highlights the prog-
nostic potential of DNA methylation in TNBC. We identified
individual potential biomarkers of patient outcome as well as
providing the first evidence to suggest that DNA methylation
could be used to stratify TNBC subtypes associated with distinct
prognostic profiles. Both observations warrant further clinical
investigation in larger independent cohorts as these signatures
may in the future provide valuable tools in the management of
TNBC.
Methods
Breast cancer tissue samples. Human tissue samples representing normal and
tumour breast from fresh frozen and formalin-fixed paraffin-embedded tissue were
obtained for this study. Only samples that were classified as triple-negative Grade 3
ductal adenocarcinomas (Supplementary Table 1) were included. The study pro-
tocol was approved by the Hunter New England Human Research Ethics Com-
mittee (NSW HREC Reference No: HREC/09/HNE/153), Newcastle, New South
Wales, Australia and the Princess Alexandra Hospital Human Research Ethics
Committee (PAH HREC)(Research Protocol: 2007/165), Brisbane, Queensland.
DNA isolation from formalin-fixed paraffin-embedded material. DNA isolation
from microdissected formalin-fixed paraffin-embedded tissue was performed using
the Gentra Puregene Genomic DNA purification tissue kit according to the
manufacturer’s instructions (Qiagen). 5 1mm cores or 5 10mm full-faced
sections were used for each extraction. The de-paraffinization step was carried out
as follows: the paraffin samples were cut into small pieces, 500 ml xylene was added
and incubated at 55 C for 5min, and the tissue was pelleted at 16,000g for 3min,
discarding the xylene. After repeating this step, 500ml 100% EtOH was added for
5min at room temperature with constant mixing and the tissue collected by
centrifugation at 16,000g for 3min. The EtOH step was repeated and the tissue
pellet dried for 10min. Then, 300 ml of cell lysis solution was added and the tube
incubated for 70 C for 10min, followed by the addition of 20 ml Proteinase K
(20mgml 1) to each sample and vortexing for 20 s and incubation in a 55 C
block overnight with constant vortexing. The following day, a further 10 ml pro-
teinase K was added, vortexed for 20 s and further incubated at 55 C until the
samples appear clear. Then, 1 ml RNase A solution (100mgml 1) was added,
mixed by inverting 25 times and incubated at 37 C for 1 h. The sample was placed
on ice to quickly cool it. Then 100 ml protein precipitation solution was added to
the cell lysates, vortexed for 20 s, incubated on ice for 5min and centrifuged at full
speed for 5min at 4 C to pellet the protein precipitate. The supernatant containing
the DNA was carefully removed into a clean microcentrifuge tube. The DNA was
precipitated with 300 ml 100% isopropanol, and 2 ml glycogen (20mgml 1) was
added if low yield was expected (o1 mg). The solutions were mixed by inversion
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(50 times) followed by centrifugation for 10min at 4 C. The DNA pellet was
washed with 70% EtOH, air-dried and dissolved in 20 ml H2O. To dissolve the
pellet, it was incubated for 1 h at 65 C with constant vortexing.
Enrichment of methylated DNA by MBDCap. The MethylMiner Methylated
DNA Enrichment Kit (Invitrogen) was used to isolate methylated DNA from
500 ng to 1 mg of genomic FFPET DNA and was sonicated to 100–500 bp. MBD-
Biotin Protein (3.5 mg) was coupled to 10ml of Dynabeads M-280 Streptavidin
according to the manufacturer’s instructions. The MBD-magnetic bead conjugates
were washed three times and re-suspended in one volume of 1 Bind/Wash
buffer. The capture reaction was performed by the addition of 500 ng to 1 mg
sonicated DNA to the MBD-magnetic beads on a rotating mixer for 1 h at room
temperature. All capture reactions were done in duplicate. The beads were washed
three times with 1 Bind/Wash buffer. The bound methylated DNA was eluted
as a single fraction with a single high-salt elution buffer (2,000mM NaCl).
Each fraction was concentrated by ethanol precipitation using 1 ml glycogen
(20 mg ml 1), 1/10 volume of 3M sodium acetate, pH 5.2 and two sample volumes
of 100% ethanol and re-suspended in 60 ml H2O. Enrichment of methylated DNA
after capture was previously assessed by quantitative PCR of control genes of
known methylation status; namely EN1 (heavily methylated) and GAPDH
(unmethylated)22.
Preparation of MBDCap-Seq libraries and Illumina sequencing. Ten nano-
grams of DNA of MBDCap-enriched DNA was prepared for Ilumina sequencing
using the Illumina ChIP-Seq DNA sample prep kit (IP-102-1001) according to the
manufacturer’s instructions. The library preparation was analysed on Agilent High
Sensitivity DNA 1000 Chip. Each sample was sequenced on one lane of the GA11x.
Computational analysis of MBDCap-Seq data. Sequenced reads were aligned to
the hg18 version of the human genome with bowtie. Reads with more than three
mismatches and reads mapping to multiple positions were removed. Finally,
multiple reads mapping to exactly the same genomic coordinate were eliminated
and only one read was retained for downstream analysis. Alignment statistics for
samples used in this study are given in Supplementary Table 5. MBDCap-Seq
platform was previously shown to interrogate CpG dense regions of the genome23.
To accurately delineate regions of the genome assayable by MBDCap-Seq, we used
fully methylated sample (SssI blood sample) to guide us to the genomic regions
attracting sequenced tags. More specifically, we applied findPeaks peak calling
utility from HOMER suite of programs56 to fully methylated sample (with
parameter settings of -style histone -size 300 -minDist 300 -tagThreshold 18) to
identify 230,655 regions covering B116Mbp of the genome. We interchangeably
refer to these regions as regions of interest or SssI regions. For each MBDCap-Seq
sample to be analysed, we computed the number of sequenced tags overlapping
SssI regions, which resulted in table of counts where columns are samples and
rows are SssI regions. We used edgeR Bioconductor package57 (http://www.
bioconductor.org/packages/release/bioc/html/edgeR.html) to model distribution of
reads between normal (n¼ 6) and tumour (n¼ 19) group of samples in the
discovery cohort. Since edgeR package does not support modelling of paired and
unpaired data simultaneously, we performed two separate analyses, a paired
analysis with six normal/tumour pairs and unpaired analysis with all the samples,
and then intersected the results. We found 822 hypermethylated and 43
hypomethylated regions at FDR threshold of 0.05 in both paired and unpaired
analyses.
Clustering of MBDCap-Seq data. The number of reads mapping to a particular
region of genome depends not just on the average level of methylation in the
region, but also on other factors, such as density of methylated CpG nucleotides.
To compare MBDCap-Seq readout to other more quantitative technologies such as
HM450K and Sequenom, we used fully methylated MBDCap-Seq sample to
normalize MBDCap-Seq readouts for samples in the discovery cohort. More
specifically, let Xi be the number of tags overlapping region i and N be the total
number of tags overlapping SssI regions in the sample to be normalized and Yi and
M be the corresponding numbers in the control sample. Then, the normalized
number of tags overlapping the region i is given by
log
Xi
N
M
Yi
þ 1
 
ð1Þ
We used normalized tag counts for heatmap visualization in Fig. 1, for comparison
with HM450K in Supplementary Fig. 2, and for comparison with Sequenom in
Supplementary Fig. 4.
Functional annotations of the genome. CpG island annotation for hg18 was
obtained from UCSC genome browser. The location of CpG island shores was
derived from CpG islands by taking ±2 Kb flanking regions and removing any
overlaps with CpG islands. RefSeq transcript annotation for hg18 was obtained
from UCSC genome browser. Promoters were defined as þ 2,000/ 100 bp around
transcription start site. Intergenic regions were defined as regions complementing
transcript regions extended to±2 Kb around the transcripts. HMEC ChromHMM
annotations for hg18 were downloaded from ENCODE. The original annotation
partitions the HMEC genome into 15 functional states (see Fig. 1b in ref. 24). In
Fig. 1c and Supplementary Fig. 1B, for brevity, we collapsed the three original
promoter states into one promoter state and the four original enhancer states into
one enhancer state.
Enrichment analysis statistical methods. For the enrichment analysis of
hypermethylated regions, we used hypergeometric test to assess the enrichment of
various functional annotations of the genome in the set of differentially methylated
regions. For a given functional annotation represented by a set of genomic regions,
fraction of SssI regions (regions assayable by MBDCap-Seq) overlapping functional
annotation was compared with the fraction of hyper-/hypomethylated regions
overlapping functional annotation using hypergeometric distribution. For the
enrichment analysis of genes affected by promoter hypermethylation, first, we used
DAVID functional annotation tool25 to carry out analysis against gene sets defined
by SP_PIR_KEYWORDS annotation. Second, we used hypergeometric test to
assess the enrichment of additional gene sets in the set of genes affected by
promoter hypermethylation26. In both the analyses, the set of 15,643 RefSeq genes
with promoters overlapping SssI regions was used as a background.
Sequenom quantitative massARRAY methylation analysis. Sequenom
MassARRAY methylation analysis was performed according to Coolen et al.58
Briefly, 500 ng of FFPET clinical sample and cell line DNA (Supplementary
Table 2) was extracted and bisulphite treated using the standard bisulphite
protocol59. As controls for the methylation analysis, whole-genome amplified DNA
(0% methylated) and M.SssI-treated DNA (100% methylated) were bisulphite
treated in parallel. The primers were designed using the EpiDesignerBETA
software from Sequenom (see Supplementary Table 6 for sequences). Each reverse
primer has a T7-promoter tag (50-CAGTAATACGACTCACTATAGGGAGAAG
GCT-30) and each forward primer has a 10-mer tag (50-AGGAAGAGAG-30). On
testing these primers on bisulphite-treated DNA, all the primers gave specific PCR
products at a Tm of 60 C. To check for potential PCR bias towards methylated or
non-methylated sequences, we used serological DNA (Millipore) as a 100%
methylated control and whole-genome amplified human blood DNA as a 0%
methylated control. The PCRs were optimized and performed in triplicate using
the conditions: 95 C for 2min, 45 cycles of 95 C for 40 s, 60 C for 1min and
72 C for 1min 30 s and final extension at 72 C for 5min. After PCR amplification,
the triplicates were pooled and a shrimp alkaline phosphatase treatment was
performed using 5 ml of the PCR product as template. Then, 2 ml of the shrimp
alkaline phosphatase-treated PCR product was taken and subjected to in vitro
transcription and RNaseA Cleavage for the T-cleavage reaction. The samples were
purified by resin treatment and spotted on a 384-well SpectroCHIP by a
MassARRAY Nanodispenser. This was followed by spectral acquisition on a
MassARRAY Analyser Compact matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry. The results were then analysed by the EpiTYPER
software V 1.0, which gives quantitative methylation levels for individual CpG sites.
The average methylation ratio was calculated by averaging the ratios obtained from
each CpG site. For the Sequenom validation, sample sizes were determined for a
two sample t-test with a two-sided alpha of 0.01, assuming five regions were to be
investigated. Assuming the difference in average methylation levels is 0.25 (tumour:
s.d.¼ 0.2, normal: s.d.¼ 0.05), to have 90% power to establish a significant
difference between tumour and normal samples, 15 samples per group were
required. The calculations are based on preliminary data from the lab on
methylation levels in breast cancer and normal samples (unpublished).
Acquisition of TCGA data. Throughout the paper, we used several molecular data
sets from TCGA breast cancer (BRCA) cohort. Clinical annotation of samples was
obtained from the marker TCGA BRCA publication (Supplementary Table 1 in ref.
13; Supplementary Table 7). Raw HM450K methylation data (Level 1) was
obtained from TCGA data portal in January 2012. Methylation data spanned 67
normal and 354 tumour ERþ samples, 16 normal and 105 tumour ER samples
and nine normal and 73 tumour TNBC samples. Processed array expression data
(Level 3) was obtained from TCGA data portal in March 2012. Expression data
spanned 52 normal and 406 tumour ERþ samples, nine normal and 118 tumour
ER samples and eight normal and 89 tumour TNBC samples. Processed RNA-
Seq expression data (Level 3) were obtained from TCGA data portal in December
2012. Expression data spanned 73 normal and 588 tumour ERþ samples, 19
normal and 174 tumour ER samples and 12 normal and 119 tumour TNBC
samples. Summary of TCGA BRCA mutation data was obtained from COSMIC
database (http://cancer.sanger.ac.uk/cosmic/study/overview?study_id=414). The
summary lists mutations in gene coding regions across patients including both
synonymous and non-synonymous amino-acid substitutions. We consider a gene
as mutated if it appears at least two times in the list (Supplementary Table 8).
Analysis of HM450K methylation data. The raw HM450K data were pre-
processed and background normalized with Bioconductor minfi package using
preprocessIllumina(..., bg.correct¼TRUE, normalize¼ ‘controls’, reference¼ 1)
command; resulting M-values were used for statistical analyses60 and beta-values
for heatmap visualizations and clustering. To identify TNBC-specific HM450K
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probes, we carried out t-test comparison between TNBC (n¼ 73) and non-TNBC
(n¼ 386) tumours. This analysis resulted in 282 probes having adj. P value o0.05
and estimated mean difference of methylation between TNBC and non-TNBC
tumours of at least 10%; these probes were declared as TNBC specific. Regions
overlapping three or more TNBC-specific probes were declared as TNBC specific.
For TNBC-specific signature, we trained a Partial Least Squares model as
implemented in the caret R package61,62 to classify tumours into TNBC and non-
TNBC based on the methylation values of 282 TNBC-specific probes. The tumour
samples in the TCGA HM450K cohort were randomly partitioned into equal-size
training/testing sets. The model parameters were derived from training set and
then applied to make predictions on the testing set. The performance of the model
was assessed using test set predictions.
Analysis of expression data. Differential expression analysis between normal
(n¼ 8) and tumour (n¼ 89) TNBC samples was carried out with Bioconductor
limma package. Since only subset of tumour samples had paired adjacent normal
samples, patient data were treated as random effect using limma’s duplicate-
Correlation(y) function. This analysis resulted in 3,017 downregulated and 3,407
upregulated genes with adj. P value o0.05 out of 17,655 genes on the array. In
Fig. 1f,g, we only considered genes with SssI regions in their promoter regions
reducing the number of downregulated, upregulated and total genes to 2,119, 2,722
and 15,543, respectively. We used log-transformed RNA-Seq expression values to
highlight the relationship between methylation and expression for number of
candidate regions in Fig. 2c and Supplementary Fig. 11.
Survival analysis. TNBC tumour samples in TCGA HM450K cohort (n¼ 73)
were clustered on the basis of methylation beta-values of 4,987 HM450K probes
overlapping the 822 hypermethylated regions. We applied consensus clustering
algorithm63 as implemented in Bioconductor ConsensusClusterPlus package
to the 4,987 73 methylation matrix with parameters maxK¼ 4, reps¼ 1000,
pItem¼ 0.8, pFeature¼ 0.8, clusterAlg¼ ‘km’, distance¼ ‘euclidean’. We used
SVD decomposition to reduce the dimension of the methylation matrix to R10
before clustering. We chose the three-cluster configuration for downstream
survival analysis.
Survival analysis was carried out using Cox proportional hazards model as
implemented in R survival package against overall survival data (Supplementary
Table 7). Survival analysis of cluster data was carried out with cluster membership
as an explanatory variable. The BRCA TNBC cohort consists of 73 patients with
HM450K methylation data and 12 events. Survival analysis of individual probes
(4,987 probes overlapping 822 hypermethylated DMRs) was carried out with probe
methylation status as explanatory variable (univariate analysis) and age, stage and
probe methylation status (multivariate analysis). Methylation status was
represented by a binary variable, high (higher than the median beta-value for the
probe) and low (smaller or equal to the median beta-value for the probe). Stage was
derived from AJCC stage in the clinical annotation of samples. Due to moderate
size of the cohort, we reduced the number of values of the stage variable to two by
collapsing stages I, IA, IB, II, IIA and IIB into one state and stages III, IIIA, IIIB,
IIIC and IV into one state. This resulted in 190 probes with methylation status
statistically and significantly (P value o0.05 in both univariate and multivariate
analyses) associated with overall survival in TCGA TNBC patients. Regional
aggregation of survival probes identified 17 hypermethylated DMRs overlapping
three or more survival probes. Fourteen regions were associated with poor
prognosis, these regions overlapped probes for which high methylation
corresponded to lower probability of survival, and three regions were
associated with good prognosis.
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